Latest stories on ATYR
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis
TipRanks53 · neutralproduct/pr
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data
TipRanks53 · neutralproduct/pr
aTyr Pharma GAAP EPS of -$0.11 beats by $0.04
Seeking Alpha61 · neutralearnings